摘要
男性患者,56岁,因晚期原发性肝癌服用推荐剂量的索拉非尼(0.4 g,q12h)治疗。用药8 d后出现发热,体温最高至39.3℃。用药11 d开始出现皮疹,再次入院。入院后停用索拉非尼并给予抗过敏治疗,5 d后症状消退。随后给予低剂量索拉非尼(0.2 g,q12h),未出现发热及皮疹。5 d后索拉非尼加至0.4 g,q12h,治疗1 d后再次出现高热及新发皮疹。遂再次停用索拉非尼,高热及皮疹渐退。停用3 d后再次降低剂量至0.2 g,q12h。患者生命体征平稳、无畏寒、发热,无新发皮疹,病情稳定。该病例可为临床医生诊断索拉非尼引起的药物热及处理方法提供借鉴。
A 56-years-old man with advanced primary hepatocarcinoma developed hyperpyrexia after re- ceiving 8 days of recommended dose of sorafenib tosylate 0.4 g ql2h treatment, his topmost body temperature was 39.3 ℃ , and from the 1 lth of administration skin rash emerged, so he was readmitted. After admissio tosylate was suspended and the patient was administered with anti-allergic treatment for 5 days. After ments his sympto tered for 5 days, n, sorafenib these treat- ms disappeared. Five days later low dose of sorafenib tosylate 0.2 g ql2h treatment was adminis- hyperpyrexia and skin rash did not occur. Then recommended dose of sorafenib tosylate 0.4 g q12h was administered for another 1 day, hyperpyrexia and skin rash reoccurred. Sorafenib was suspended again for 3 days and his symptoms improved. Then low dose of sorafenib tosylate （0.2 g q12h） was administered again, his vital sign and condition were stable without hyperpyrexia and new skin rash. This paper will be helpful to clini- cal physicians in diagnosing and managing drug fever.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2013年第2期248-250,共3页
Chinese Journal of New Drugs
关键词
甲苯磺酸索拉非尼
药物不良反应
高热
皮疹
原发性肝癌
sorafenib tosylate
adverse drug reaction
hyperpyrexia
skin rash
primary hepatocellularcarcinoma
